FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to chimeric antigenic receptors (CAR), and can be used in medicine for treating diseases of plasma cells, which are characterized by expression of B-cell maturation antigen (BCMA) and transmembrane activator receptor, calcium modulator and cyclophilin ligand activator (TACI). CAR containing shortened proliferation inducing ligand (APRIL), which binds both with BCMA, and with TACI; a spacer domain; transmembrane domain and intracellular T-cell signal domain.
EFFECT: invention enables to obtain CAR, which effectively binds BCMA and TACI.
26 cl, 16 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
| CELL | 2016 |
|
RU2729158C2 |
| CHIMERIC ANTIGENIC RECEPTORS AIMED AT ANTIGEN OF AGING OF B-CELLS | 2016 |
|
RU2706582C2 |
| COMBINATION THERAPY FOR THE TREATMENT OF BCMA-RELATED CANCER AND AUTOIMMUNE DISORDERS | 2018 |
|
RU2799762C2 |
| CHIMERIC ANTIGENIC RECEPTOR | 2015 |
|
RU2685479C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| CHIMERIC ANTIGEN RECEPTORS TO MYELOMA KAPPA ANTIGEN AND VERSIONS OF THEIR APPLICATION | 2016 |
|
RU2743188C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| OPTIMISED FUSED PROTEIN TACI-FC | 2008 |
|
RU2433141C2 |
